Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|December 27, 2024

Tools for PTSD Diagnosis

Author(s)Arash Javanbakht, MD, Matthew Robinson, PhD, Tory Woodard, NP

A panelist discusses how clinicians employ a range of diagnostic tools for posttraumatic stress disorder (PTSD) assessment, including structured clinical interviews, standardized questionnaires such as the PCL-5, trauma screening instruments, and detailed behavioral observations to ensure accurate diagnosis and appropriate treatment planning.

Episodes in this series

4 experts are featured in this series.

EP. 1 PTSD in Society

4 experts are featured in this series.

EP. 2 PTSD Risk Factors and Changes in the Brain

4 experts are featured in this series.

EP. 3 PTSD Symptoms

4 experts are featured in this series.

EP. 4 PTSD Diagnosis and Challenges

4 experts are featured in this series.

EP. 5 Tools for PTSD Diagnosis

4 experts are featured in this series.

EP. 6 PTSD Diagnosis in Clinical Settings

4 experts are featured in this series.

EP. 7 Treatment Options for PTSD

4 experts are featured in this series.

EP. 8 Use of PTSD Treatments in Clinical Practice

4 experts are featured in this series.

EP. 9 Emerging Treatments in PTSD

4 experts are featured in this series.

EP. 10 Concluding Thoughts on PTSD Management

4 experts are featured in this series.

EP. 11 Patient Case: Trauma and Impact of PTSD on Quality of Life

PTSD

EP. 12 Panel Shares Top 7 Insights Into Addressing PTSD

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

psychedelic

Podcast: Exploring Entactogens With Hiroe Imai Hu, DO, and James W. Murrough, MD, PhD

ByJenessa Johnston, PhD,Hiroe Hu, DO,James Murrough, MD, PhD

August 13th 2026

Entactogens as a New Frontier for Mood and Anxiety Disorders: A Conversation With Hiroe Imai Hu, DO, and James W. Murrough, MD, PhD

ByJenessa Johnston, PhD

August 13th 2026

trauma

Podcast: Navigating Trauma, Transformations, and Truth With Emily Lafferman, MD

ByFrank A. Clark, MD,Emily Lafferman, MD

August 5th 2026

Screening for MDD: Distinguishing Depression From Grief and Medical Mimics

ByGus Alva, MD ,Anita H. Clayton, MD,Charles Debattista, MD,Lara Shirikjian, MD ,Hara Oyedeji, DNP, PMHNP-BC

July 28th 2026

Recognizing MDD in Practice: Presentation, Risk Factors, and Delayed Diagnosis

ByGus Alva, MD ,Anita H. Clayton, MD,Charles Debattista, MD,Lara Shirikjian, MD ,Hara Oyedeji, DNP, PMHNP-BC

July 28th 2026

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Kratom Component in Clinical Trial for Opioid Use Disorder

Why Cultural Context Matters in Psychiatric Assessment

FDA Feedback Paves Way for New IND Filing for PT00114 in Generalized Anxiety Disorder

NIDA Awards PleoPharma $6.5 Million Grant to Advance Phase 3 Trial of PP-01 for Cannabis Use Disorder

A Practical Role for Long-Acting Buprenorphine in Opioid Use Disorder Care